link_id stringlengths 25 25 | evidence_group_id stringlengths 22 22 | pmid int64 1.8M 42.2M | nct_id stringlengths 11 11 | claim_type stringclasses 6
values | claim_direction stringclasses 6
values | claim_strength stringclasses 3
values | n_results int64 0 126 | outcome_types_present stringclasses 5
values | result_ids stringclasses 249
values | checkability stringclasses 2
values | verification stringclasses 1
value | evidence_span stringclasses 21
values |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CLAIM_RESULT_07e5ed02ac79 | CLUST_4e7a026f3ab4be13 | 26,995,233 | NCT00021528 | association_claim | improved | directionally_supported | 0 | null | null | unverifiable_no_results | not_assessed | associated with |
CLAIM_RESULT_86b4b602d294 | CLUST_51253c61952046de | 26,822,799 | NCT00729755 | superiority_claim | unclear | source_reported | 0 | null | null | unverifiable_no_results | not_assessed | increased |
CLAIM_RESULT_45226aef970c | CLUST_51253c61952046de | 26,822,799 | NCT00729755 | efficacy_claim | unclear | source_reported | 0 | null | null | unverifiable_no_results | not_assessed | efficacy |
CLAIM_RESULT_e5cc4a83d94b | CLUST_4e59ecfc7ac762fa | 26,773,906 | NCT00969150 | efficacy_claim | unclear | statistically_supported | 2 | PRIMARY; SECONDARY | RESULT_e0e30f1b275e; RESULT_a0197926ed75 | checkable | not_assessed | efficacy |
CLAIM_RESULT_2d9553c27009 | CLUST_4e59ecfc7ac762fa | 26,773,906 | NCT00969709 | efficacy_claim | unclear | statistically_supported | 2 | PRIMARY; SECONDARY | RESULT_b57b9fd2ea19; RESULT_687b7b0f9afc | checkable | not_assessed | efficacy |
CLAIM_RESULT_0940726ca95f | CLUST_4e59ecfc7ac762fa | 26,773,906 | NCT01034462 | efficacy_claim | unclear | statistically_supported | 2 | PRIMARY; SECONDARY | RESULT_97d36a6be50e; RESULT_1a05d9c1a21b | checkable | not_assessed | efficacy |
CLAIM_RESULT_27bb6c0ce3b4 | CLUST_4e59ecfc7ac762fa | 26,773,906 | NCT01377194 | efficacy_claim | unclear | statistically_supported | 2 | PRIMARY; SECONDARY | RESULT_66de97cd21b0; RESULT_431e01061a75 | checkable | not_assessed | efficacy |
CLAIM_RESULT_eb0ec545d30f | CLUST_ba8355c38bd1b3b0 | 26,743,100 | NCT00052091 | superiority_claim | improved | statistically_supported | 0 | null | null | unverifiable_no_results | not_assessed | more effective than |
CLAIM_RESULT_39bdfa991487 | CLUST_456646ed91651f84 | 26,702,639 | NCT00985686 | superiority_claim | improved | statistically_supported | 7 | PRIMARY; SECONDARY | RESULT_6c2633f51404; RESULT_b2786165146f; RESULT_6b2b01200895; RESULT_f28ba2861735; RESULT_ac712933db33; RESULT_afcadcf7b691; RESULT_6eaed53b1afe | checkable | not_assessed | reduced |
CLAIM_RESULT_e8a06a42c203 | CLUST_e4dde6cd0389d48f | 26,683,252 | NCT01401569 | superiority_claim | improved | statistically_supported | 0 | null | null | unverifiable_no_results | not_assessed | reduced |
CLAIM_RESULT_fff77f6fe72c | CLUST_e4dde6cd0389d48f | 26,683,252 | NCT01401569 | no_difference_claim | no_difference | statistically_supported | 0 | null | null | unverifiable_no_results | not_assessed | did not differ |
CLAIM_RESULT_5fcfc0e980ed | CLUST_e4dde6cd0389d48f | 26,683,252 | NCT01401569 | efficacy_claim | improved | statistically_supported | 0 | null | null | unverifiable_no_results | not_assessed | efficacy |
CLAIM_RESULT_e62665767809 | CLUST_4d1a8442628a9e06 | 26,654,720 | NCT02306551 | superiority_claim | worsened | directionally_supported | 0 | null | null | unverifiable_no_results | not_assessed | increased |
CLAIM_RESULT_e070fadead89 | CLUST_e7237c12c254ae5e | 26,646,751 | NCT01546922 | superiority_claim | improved | statistically_supported | 5 | PRIMARY; SECONDARY | RESULT_0b1ff455f135; RESULT_87f8e7af229b; RESULT_c904f2fea752; RESULT_d0989a69d167; RESULT_f6a7d2bd9bb5 | checkable | not_assessed | increased |
CLAIM_RESULT_2f6769f55e88 | CLUST_26d50feb55a190c9 | 26,646,040 | NCT01383915 | association_claim | improved | directionally_supported | 0 | null | null | unverifiable_no_results | not_assessed | associated with |
CLAIM_RESULT_3d30706f25a1 | CLUST_4ac918e56e5082e8 | 26,621,218 | NCT02358343 | efficacy_claim | unclear | source_reported | 15 | PRIMARY; SECONDARY | RESULT_1eeb1dde63a6; RESULT_4830f7d88ac9; RESULT_8c92a962292e; RESULT_3b934513dd2f; RESULT_79920e0c869a; RESULT_40f8711bb578; RESULT_2ab0e676d48b; RESULT_3ca9a27e8521; RESULT_d2a51dfa672b; RESULT_8c34b54cfc1a; RESULT_0aadbbda5b93; RESULT_9f9ce6da693e; RESULT_9abc8cb4c2db; RESULT_736f63c08481; RESULT_b74c1c247bad | checkable | not_assessed | efficacy |
CLAIM_RESULT_1b9d6744ac0c | CLUST_985bc9cea1a31059 | 26,613,389 | NCT00955955 | association_claim | improved | directionally_supported | 2 | PRIMARY; SECONDARY | RESULT_c07cbba67c34; RESULT_d8cfb7cc162b | checkable | not_assessed | associated with |
CLAIM_RESULT_be42560c1a1f | CLUST_4ddbf0b168fc7d8a | 26,598,474 | NCT00612313 | no_difference_claim | no_difference | statistically_supported | 6 | PRIMARY; SECONDARY | RESULT_933177ae6940; RESULT_85abb2ff1acd; RESULT_dbcd117d2c72; RESULT_1301f0861738; RESULT_4b0b7d0ee123; RESULT_988c9c8c4705 | checkable | not_assessed | no difference |
CLAIM_RESULT_5e3c5d0aa9a1 | CLUST_a64da054e5c9f4dd | 26,597,295 | NCT02292394 | efficacy_claim | unclear | source_reported | 0 | null | null | unverifiable_no_results | not_assessed | efficacy |
CLAIM_RESULT_47a0d4686e71 | CLUST_21ca066d76bf7192 | 26,578,205 | NCT00319540 | superiority_claim | improved | directionally_supported | 0 | null | null | unverifiable_no_results | not_assessed | increased |
CLAIM_RESULT_c27066d77189 | CLUST_21ca066d76bf7192 | 26,578,205 | NCT00319540 | association_claim | improved | directionally_supported | 0 | null | null | unverifiable_no_results | not_assessed | associated with |
CLAIM_RESULT_2b3635471457 | CLUST_21ca066d76bf7192 | 26,578,205 | NCT00319540 | efficacy_claim | improved | directionally_supported | 0 | null | null | unverifiable_no_results | not_assessed | efficacy |
CLAIM_RESULT_09ae53f6c7df | CLUST_21ca066d76bf7192 | 26,578,205 | NCT02501226 | superiority_claim | improved | directionally_supported | 0 | null | null | unverifiable_no_results | not_assessed | increased |
CLAIM_RESULT_2b313afcd220 | CLUST_21ca066d76bf7192 | 26,578,205 | NCT02501226 | association_claim | improved | directionally_supported | 0 | null | null | unverifiable_no_results | not_assessed | associated with |
CLAIM_RESULT_0185aa9e1af3 | CLUST_21ca066d76bf7192 | 26,578,205 | NCT02501226 | efficacy_claim | improved | directionally_supported | 0 | null | null | unverifiable_no_results | not_assessed | efficacy |
CLAIM_RESULT_0c9d57669468 | CLUST_cc8afc305db05573 | 26,558,530 | NCT02440594 | association_claim | associated | source_reported | 5 | PRIMARY; SECONDARY | RESULT_6b5b22a8f187; RESULT_8bd6958ca430; RESULT_afa172345462; RESULT_cab9d3efec5c; RESULT_cb3fc6f70005 | checkable | not_assessed | associated with |
CLAIM_RESULT_d7176a473ba1 | CLUST_2fc17df4e9131d59 | 26,552,942 | NCT01423240 | superiority_claim | improved | directionally_supported | 0 | null | null | unverifiable_no_results | not_assessed | increased |
CLAIM_RESULT_5970f136e294 | CLUST_2fc17df4e9131d59 | 26,552,942 | NCT01423240 | safety_claim | improved | directionally_supported | 0 | null | null | unverifiable_no_results | not_assessed | well tolerated |
CLAIM_RESULT_587d1eb7b469 | CLUST_2fc17df4e9131d59 | 26,552,942 | NCT01423240 | association_claim | improved | directionally_supported | 0 | null | null | unverifiable_no_results | not_assessed | associated with |
CLAIM_RESULT_0a7024fe5855 | CLUST_2fc17df4e9131d59 | 26,552,942 | NCT01423240 | efficacy_claim | improved | directionally_supported | 0 | null | null | unverifiable_no_results | not_assessed | efficacy |
CLAIM_RESULT_345017ffaf35 | CLUST_16172ee1c2f52eb8 | 26,541,814 | NCT01396447 | safety_claim | unclear | statistically_supported | 2 | PRIMARY; SECONDARY | RESULT_baac61385b32; RESULT_329729d58375 | checkable | not_assessed | well tolerated |
CLAIM_RESULT_dff0a5b8e3ae | CLUST_16172ee1c2f52eb8 | 26,541,814 | NCT01396447 | efficacy_claim | unclear | statistically_supported | 2 | PRIMARY; SECONDARY | RESULT_baac61385b32; RESULT_329729d58375 | checkable | not_assessed | efficacy |
CLAIM_RESULT_d227f1a90690 | CLUST_96833a3e8e7a2eb7 | 26,531,124 | NCT02371291 | association_claim | associated | source_reported | 0 | null | null | unverifiable_no_results | not_assessed | associated with |
CLAIM_RESULT_29af8e1a6e73 | CLUST_96833a3e8e7a2eb7 | 26,531,124 | NCT02371291 | efficacy_claim | associated | source_reported | 0 | null | null | unverifiable_no_results | not_assessed | efficacy |
CLAIM_RESULT_3de736765d5f | CLUST_03adc1f3e5bc58d2 | 26,529,118 | NCT00660062 | efficacy_claim | unclear | statistically_supported | 0 | null | null | unverifiable_no_results | not_assessed | efficacy |
CLAIM_RESULT_7c0049a272c6 | CLUST_259cdbff49134f22 | 26,471,432 | NCT00602290 | association_claim | associated | source_reported | 2 | PRIMARY; SECONDARY | RESULT_84352fb95434; RESULT_8b43cc4c0de3 | checkable | not_assessed | associated with |
CLAIM_RESULT_3b988c5424e3 | CLUST_9eeae36d632634ae | 26,466,310 | NCT00879255 | association_claim | associated | source_reported | 3 | PRIMARY | RESULT_3c6eeda329a1; RESULT_6e7964420bba; RESULT_2aab7477ade0 | checkable | not_assessed | associated with |
CLAIM_RESULT_dfa346b51201 | CLUST_3af7ba6ce785a99f | 26,424,428 | NCT01325532 | no_difference_claim | no_difference | statistically_supported | 3 | PRIMARY; SECONDARY | RESULT_2b199bc82bff; RESULT_c88343db2992; RESULT_bcb965a4cbce | checkable | not_assessed | no significant difference |
CLAIM_RESULT_b9cf9c400e94 | CLUST_3af7ba6ce785a99f | 26,424,428 | NCT01325532 | efficacy_claim | improved | statistically_supported | 3 | PRIMARY; SECONDARY | RESULT_2b199bc82bff; RESULT_c88343db2992; RESULT_bcb965a4cbce | checkable | not_assessed | efficacy |
CLAIM_RESULT_9d9aa2c9fca3 | CLUST_0f2254e693730824 | 26,423,182 | NCT00892047 | association_claim | improved | directionally_supported | 6 | PRIMARY; SECONDARY | RESULT_e74b693bc59a; RESULT_cbb9d7c8af75; RESULT_3242fb2e90e0; RESULT_02d7fd1f5293; RESULT_aea42aff5a34; RESULT_083e3339a3e4 | checkable | not_assessed | associated with |
CLAIM_RESULT_6481909da08d | CLUST_0f2254e693730824 | 26,423,182 | NCT00892047 | efficacy_claim | improved | statistically_supported | 6 | PRIMARY; SECONDARY | RESULT_e74b693bc59a; RESULT_cbb9d7c8af75; RESULT_3242fb2e90e0; RESULT_02d7fd1f5293; RESULT_aea42aff5a34; RESULT_083e3339a3e4 | checkable | not_assessed | efficacy |
CLAIM_RESULT_0db72bc8ffd2 | CLUST_bfdb34cb80138a1a | 26,421,634 | NCT02178696 | superiority_claim | associated | statistically_supported | 7 | PRIMARY; SECONDARY | RESULT_0bb635688759; RESULT_97916f8a854f; RESULT_a1823a8f9f77; RESULT_c5361493cf45; RESULT_a8e15e807ff1; RESULT_8e0ccc2bd0e1; RESULT_ff7cf3d82cad | checkable | not_assessed | increased |
CLAIM_RESULT_a98467cfd49f | CLUST_bfdb34cb80138a1a | 26,421,634 | NCT02178696 | association_claim | associated | source_reported | 7 | PRIMARY; SECONDARY | RESULT_0bb635688759; RESULT_97916f8a854f; RESULT_a1823a8f9f77; RESULT_c5361493cf45; RESULT_a8e15e807ff1; RESULT_8e0ccc2bd0e1; RESULT_ff7cf3d82cad | checkable | not_assessed | associated with |
CLAIM_RESULT_87ab7dd7cc62 | CLUST_09d68f5158552713 | 26,414,759 | NCT01028625 | superiority_claim | improved | statistically_supported | 0 | null | null | unverifiable_no_results | not_assessed | reduced |
CLAIM_RESULT_3e4c99023fcf | CLUST_09d68f5158552713 | 26,414,759 | NCT01028625 | no_difference_claim | no_difference | statistically_supported | 0 | null | null | unverifiable_no_results | not_assessed | did not differ |
CLAIM_RESULT_8eed8904b298 | CLUST_09d68f5158552713 | 26,414,759 | NCT01028625 | efficacy_claim | improved | statistically_supported | 0 | null | null | unverifiable_no_results | not_assessed | efficacy |
CLAIM_RESULT_0e08c0409515 | CLUST_4e7a026f3ab4be13 | 26,384,013 | NCT00021528 | association_claim | associated | source_reported | 0 | null | null | unverifiable_no_results | not_assessed | increased |
CLAIM_RESULT_11ba8a5d5158 | CLUST_4e7a026f3ab4be13 | 26,384,013 | NCT00021528 | association_claim | associated | source_reported | 0 | null | null | unverifiable_no_results | not_assessed | correlated with |
CLAIM_RESULT_13a303e99169 | CLUST_4e7a026f3ab4be13 | 26,374,703 | NCT02263872 | superiority_claim | unclear | source_reported | 0 | null | null | unverifiable_no_results | not_assessed | increased |
CLAIM_RESULT_2afab1014d4e | CLUST_9cb8f704a13306fb | 26,371,617 | NCT01065311 | superiority_claim | unclear | source_reported | 0 | null | null | unverifiable_no_results | not_assessed | superior to |
CLAIM_RESULT_47d314b2d9bd | CLUST_9cb8f704a13306fb | 26,371,617 | NCT01065311 | efficacy_claim | unclear | source_reported | 0 | null | null | unverifiable_no_results | not_assessed | efficacy |
CLAIM_RESULT_0d2f5a86f896 | CLUST_2fa04fcaeba2f942 | 26,360,086 | NCT01287494 | efficacy_claim | improved | statistically_supported | 0 | null | null | unverifiable_no_results | not_assessed | improved outcomes |
CLAIM_RESULT_00bff893c376 | CLUST_6318117fa8d081c7 | 26,359,900 | NCT01663649 | superiority_claim | unclear | statistically_supported | 0 | null | null | unverifiable_no_results | not_assessed | increased |
CLAIM_RESULT_8ab7008e57fe | CLUST_1fc4bc12851a1cbe | 26,345,179 | NCT01045655 | superiority_claim | improved | statistically_supported | 0 | null | null | unverifiable_no_results | not_assessed | increased |
CLAIM_RESULT_f77e720ea497 | CLUST_1fc4bc12851a1cbe | 26,345,179 | NCT01045655 | association_claim | improved | directionally_supported | 0 | null | null | unverifiable_no_results | not_assessed | associated with |
CLAIM_RESULT_d7f144b86e4b | CLUST_d071d6dcc914fe66 | 26,318,271 | NCT00928980 | no_difference_claim | no_difference | source_reported | 0 | null | null | unverifiable_no_results | not_assessed | no significant difference |
CLAIM_RESULT_7d78bc205f05 | CLUST_b48dde4cf52f0eb8 | 26,313,133 | NCT00419471 | superiority_claim | associated | source_reported | 0 | null | null | unverifiable_no_results | not_assessed | more effective than |
CLAIM_RESULT_191c525da7d6 | CLUST_b48dde4cf52f0eb8 | 26,313,133 | NCT00419471 | association_claim | associated | source_reported | 0 | null | null | unverifiable_no_results | not_assessed | associated with |
CLAIM_RESULT_eac572477a74 | CLUST_c5c074bf2383832f | 26,311,446 | NCT00594711 | superiority_claim | unclear | source_reported | 0 | null | null | unverifiable_no_results | not_assessed | increased |
CLAIM_RESULT_baefcda90c34 | CLUST_466eba9709771c78 | 26,301,771 | NCT01360632 | safety_claim | unclear | statistically_supported | 24 | PRIMARY; SECONDARY | RESULT_56eabbfd9dc0; RESULT_a99361d4e140; RESULT_c57ab643c9cb; RESULT_95717e1e7fc6; RESULT_9851fa1ed5b4; RESULT_0e0fc694c62a; RESULT_4fb718df1574; RESULT_e2a892cea259; RESULT_54da2c1d81aa; RESULT_f880e622bd02; RESULT_f2e5d7ecc1c5; RESULT_847a4d430abf; RESULT_838ba3770777; RESULT_ba851d5bd541; RESULT_3c1710f3ca56; RESUL... | checkable | not_assessed | well tolerated |
CLAIM_RESULT_db9d9a3393b5 | CLUST_466eba9709771c78 | 26,301,771 | NCT01360632 | efficacy_claim | unclear | statistically_supported | 24 | PRIMARY; SECONDARY | RESULT_56eabbfd9dc0; RESULT_a99361d4e140; RESULT_c57ab643c9cb; RESULT_95717e1e7fc6; RESULT_9851fa1ed5b4; RESULT_0e0fc694c62a; RESULT_4fb718df1574; RESULT_e2a892cea259; RESULT_54da2c1d81aa; RESULT_f880e622bd02; RESULT_f2e5d7ecc1c5; RESULT_847a4d430abf; RESULT_838ba3770777; RESULT_ba851d5bd541; RESULT_3c1710f3ca56; RESUL... | checkable | not_assessed | efficacy |
CLAIM_RESULT_4629198ede2d | CLUST_466eba9709771c78 | 26,301,701 | NCT01360645 | superiority_claim | improved | statistically_supported | 24 | PRIMARY; SECONDARY | RESULT_c0243b6955a4; RESULT_3d42ceaae613; RESULT_4f597d614bcc; RESULT_19e598628adf; RESULT_beab72d1cbec; RESULT_30b266c84384; RESULT_71aecdaa431b; RESULT_9f252ed18c6b; RESULT_fc4323d68852; RESULT_a1af5c67f06d; RESULT_08329a926d84; RESULT_8b788683e322; RESULT_2e463e3b30b9; RESULT_bed7dbc6c76d; RESULT_8a07763656a2; RESUL... | checkable | not_assessed | reduced |
CLAIM_RESULT_1eee07324112 | CLUST_466eba9709771c78 | 26,301,701 | NCT01360645 | safety_claim | improved | statistically_supported | 24 | PRIMARY; SECONDARY | RESULT_c0243b6955a4; RESULT_3d42ceaae613; RESULT_4f597d614bcc; RESULT_19e598628adf; RESULT_beab72d1cbec; RESULT_30b266c84384; RESULT_71aecdaa431b; RESULT_9f252ed18c6b; RESULT_fc4323d68852; RESULT_a1af5c67f06d; RESULT_08329a926d84; RESULT_8b788683e322; RESULT_2e463e3b30b9; RESULT_bed7dbc6c76d; RESULT_8a07763656a2; RESUL... | checkable | not_assessed | well tolerated |
CLAIM_RESULT_7b41e2e6ffc5 | CLUST_466eba9709771c78 | 26,301,701 | NCT01360645 | efficacy_claim | improved | statistically_supported | 24 | PRIMARY; SECONDARY | RESULT_c0243b6955a4; RESULT_3d42ceaae613; RESULT_4f597d614bcc; RESULT_19e598628adf; RESULT_beab72d1cbec; RESULT_30b266c84384; RESULT_71aecdaa431b; RESULT_9f252ed18c6b; RESULT_fc4323d68852; RESULT_a1af5c67f06d; RESULT_08329a926d84; RESULT_8b788683e322; RESULT_2e463e3b30b9; RESULT_bed7dbc6c76d; RESULT_8a07763656a2; RESUL... | checkable | not_assessed | efficacy |
CLAIM_RESULT_08241718ab01 | CLUST_081d2de58561fa67 | 26,291,335 | NCT01766401 | safety_claim | unclear | statistically_supported | 2 | PRIMARY; SECONDARY | RESULT_ee21b55974d4; RESULT_adc02ff5ef2c | checkable | not_assessed | adverse events were |
CLAIM_RESULT_fce4d31cf37f | CLUST_081d2de58561fa67 | 26,291,335 | NCT01766401 | efficacy_claim | unclear | statistically_supported | 2 | PRIMARY; SECONDARY | RESULT_ee21b55974d4; RESULT_adc02ff5ef2c | checkable | not_assessed | efficacy |
CLAIM_RESULT_a90720069e97 | CLUST_0f2254e693730824 | 26,288,246 | NCT00892047 | association_claim | associated | source_reported | 6 | PRIMARY; SECONDARY | RESULT_e74b693bc59a; RESULT_cbb9d7c8af75; RESULT_3242fb2e90e0; RESULT_02d7fd1f5293; RESULT_aea42aff5a34; RESULT_083e3339a3e4 | checkable | not_assessed | associated with |
CLAIM_RESULT_3e38306ed7f6 | CLUST_6318117fa8d081c7 | 26,282,359 | NCT00693849 | superiority_claim | improved | directionally_supported | 0 | null | null | unverifiable_no_results | not_assessed | reduced |
CLAIM_RESULT_9edddff8d7ae | CLUST_0f2254e693730824 | 26,278,231 | NCT00892047 | no_difference_claim | no_difference | source_reported | 6 | PRIMARY; SECONDARY | RESULT_e74b693bc59a; RESULT_cbb9d7c8af75; RESULT_3242fb2e90e0; RESULT_02d7fd1f5293; RESULT_aea42aff5a34; RESULT_083e3339a3e4 | checkable | not_assessed | did not differ |
CLAIM_RESULT_13052d5806fc | CLUST_9de960c679f3942a | 26,278,222 | NCT01139060 | superiority_claim | improved | statistically_supported | 0 | null | null | unverifiable_no_results | not_assessed | more effective than |
CLAIM_RESULT_6a7d7f7dbec0 | CLUST_4ac918e56e5082e8 | 26,260,780 | NCT02278224 | efficacy_claim | unclear | source_reported | 0 | null | null | unverifiable_no_results | not_assessed | effective in |
CLAIM_RESULT_ee217342c0d3 | CLUST_451956d475ce3c85 | 26,249,300 | NCT00324701 | non_inferiority_claim | no_difference | statistically_supported | 2 | PRIMARY; SECONDARY | RESULT_97c20874ba3d; RESULT_4a228f4364f2 | checkable | not_assessed | non-inferior |
CLAIM_RESULT_a69d1675942e | CLUST_451956d475ce3c85 | 26,249,300 | NCT00324701 | no_difference_claim | no_difference | statistically_supported | 2 | PRIMARY; SECONDARY | RESULT_97c20874ba3d; RESULT_4a228f4364f2 | checkable | not_assessed | no significant difference |
CLAIM_RESULT_f1b4087108bb | CLUST_451956d475ce3c85 | 26,249,300 | NCT00324701 | association_claim | no_difference | source_reported | 2 | PRIMARY; SECONDARY | RESULT_97c20874ba3d; RESULT_4a228f4364f2 | checkable | not_assessed | associated with |
CLAIM_RESULT_9b163cc5ded4 | CLUST_7898a45eddc908ad | 26,187,603 | NCT01065597 | efficacy_claim | unclear | statistically_supported | 4 | PRIMARY; SECONDARY | RESULT_c909b7be8604; RESULT_b55ac1aff613; RESULT_02eeea347d1b; RESULT_d39eadd4e244 | checkable | not_assessed | effective in |
CLAIM_RESULT_6dd090d147e5 | CLUST_1f2e3a97478e0913 | 26,176,930 | NCT01894815 | non_inferiority_claim | non_inferior | directionally_supported | 0 | null | null | unverifiable_no_results | not_assessed | non-inferior |
CLAIM_RESULT_a964068fb2ae | CLUST_1f2e3a97478e0913 | 26,176,930 | NCT01894815 | efficacy_claim | non_inferior | directionally_supported | 0 | null | null | unverifiable_no_results | not_assessed | efficacy |
CLAIM_RESULT_535b75c3a29b | CLUST_8f7d7859f06d874b | 26,142,691 | NCT01309776 | association_claim | associated | source_reported | 0 | null | null | unverifiable_no_results | not_assessed | associated with |
CLAIM_RESULT_9da7f4e7431c | CLUST_0ee8084afed41619 | 26,132,682 | NCT01707706 | safety_claim | associated | statistically_supported | 0 | null | null | unverifiable_no_results | not_assessed | well tolerated |
CLAIM_RESULT_e8cfbe0ba2fc | CLUST_0ee8084afed41619 | 26,132,682 | NCT01707706 | association_claim | associated | source_reported | 0 | null | null | unverifiable_no_results | not_assessed | associated with |
CLAIM_RESULT_6867c3ed64f6 | CLUST_0ee8084afed41619 | 26,132,682 | NCT01707706 | efficacy_claim | associated | statistically_supported | 0 | null | null | unverifiable_no_results | not_assessed | efficacy |
CLAIM_RESULT_e778d7cd3a54 | CLUST_85ec21074da18cfd | 26,085,041 | NCT00633399 | efficacy_claim | unclear | source_reported | 3 | PRIMARY; SECONDARY | RESULT_b3c3f270474c; RESULT_84fced2f1bc7; RESULT_aa0e05e3ddcf | checkable | not_assessed | efficacy |
CLAIM_RESULT_8b416bad9394 | CLUST_c5a1f352441837d5 | 26,039,688 | NCT01473381 | superiority_claim | improved | directionally_supported | 3 | PRIMARY; SECONDARY | RESULT_61036c1ae002; RESULT_8407db37031c; RESULT_75b570438544 | checkable | not_assessed | increased |
CLAIM_RESULT_8bd5d97ce207 | CLUST_69875f62d285d5f7 | 26,035,186 | NCT01179516 | no_difference_claim | no_difference | source_reported | 6 | PRIMARY; SECONDARY | RESULT_813de79a30d3; RESULT_5d68b441a625; RESULT_4bef8596f2a7; RESULT_ac9d2735e45a; RESULT_1b34cb7e7795; RESULT_8863ad83c831 | checkable | not_assessed | did not differ |
CLAIM_RESULT_e164faab94db | CLUST_69875f62d285d5f7 | 26,035,186 | NCT01179516 | safety_claim | no_difference | source_reported | 6 | PRIMARY; SECONDARY | RESULT_813de79a30d3; RESULT_5d68b441a625; RESULT_4bef8596f2a7; RESULT_ac9d2735e45a; RESULT_1b34cb7e7795; RESULT_8863ad83c831 | checkable | not_assessed | adverse events were |
CLAIM_RESULT_b7191fc0bd8e | CLUST_69875f62d285d5f7 | 26,035,186 | NCT01179516 | efficacy_claim | no_difference | source_reported | 6 | PRIMARY; SECONDARY | RESULT_813de79a30d3; RESULT_5d68b441a625; RESULT_4bef8596f2a7; RESULT_ac9d2735e45a; RESULT_1b34cb7e7795; RESULT_8863ad83c831 | checkable | not_assessed | efficacy |
CLAIM_RESULT_4f361050a60d | CLUST_3ab193df5bd3d7d1 | 26,035,185 | NCT01163266 | superiority_claim | improved | statistically_supported | 6 | PRIMARY; SECONDARY | RESULT_3969acb5549d; RESULT_702f3353cbd2; RESULT_550ef2137739; RESULT_b5a72fb55899; RESULT_28833eaa9007; RESULT_8520b5c834c2 | checkable | not_assessed | reduced |
CLAIM_RESULT_0970425bf15a | CLUST_3ab193df5bd3d7d1 | 26,035,185 | NCT01163266 | safety_claim | improved | statistically_supported | 6 | PRIMARY; SECONDARY | RESULT_3969acb5549d; RESULT_702f3353cbd2; RESULT_550ef2137739; RESULT_b5a72fb55899; RESULT_28833eaa9007; RESULT_8520b5c834c2 | checkable | not_assessed | well tolerated |
CLAIM_RESULT_3730ac3bf484 | CLUST_3ab193df5bd3d7d1 | 26,035,185 | NCT01163266 | efficacy_claim | improved | statistically_supported | 6 | PRIMARY; SECONDARY | RESULT_3969acb5549d; RESULT_702f3353cbd2; RESULT_550ef2137739; RESULT_b5a72fb55899; RESULT_28833eaa9007; RESULT_8520b5c834c2 | checkable | not_assessed | efficacy |
CLAIM_RESULT_f9588979bb9b | CLUST_69edffbf99d3cb90 | 28,086,004 | NCT01627782 | superiority_claim | improved | directionally_supported | 16 | PRIMARY; SECONDARY | RESULT_e1e9327058b3; RESULT_7c5c33a2c68f; RESULT_737e8ad1e640; RESULT_f2a65dd682c2; RESULT_8fed8a017760; RESULT_dec24b3409d7; RESULT_76dcb43fdc01; RESULT_a508a83145eb; RESULT_1b83681ca18f; RESULT_de0c80c234ca; RESULT_d7284ea8990a; RESULT_cd7e7f83d9a1; RESULT_49fb3489b8d3; RESULT_19ce89194ef3; RESULT_40de3b06ec1b; RESUL... | checkable | not_assessed | reduced |
CLAIM_RESULT_e45a47ac5323 | CLUST_69edffbf99d3cb90 | 28,086,004 | NCT01627782 | efficacy_claim | improved | directionally_supported | 16 | PRIMARY; SECONDARY | RESULT_e1e9327058b3; RESULT_7c5c33a2c68f; RESULT_737e8ad1e640; RESULT_f2a65dd682c2; RESULT_8fed8a017760; RESULT_dec24b3409d7; RESULT_76dcb43fdc01; RESULT_a508a83145eb; RESULT_1b83681ca18f; RESULT_de0c80c234ca; RESULT_d7284ea8990a; RESULT_cd7e7f83d9a1; RESULT_49fb3489b8d3; RESULT_19ce89194ef3; RESULT_40de3b06ec1b; RESUL... | checkable | not_assessed | efficacy |
CLAIM_RESULT_f87900db090a | CLUST_69edffbf99d3cb90 | 28,086,004 | NCT01640080 | superiority_claim | improved | directionally_supported | 0 | null | null | unverifiable_no_results | not_assessed | reduced |
CLAIM_RESULT_b78baa71b487 | CLUST_69edffbf99d3cb90 | 28,086,004 | NCT01640080 | efficacy_claim | improved | directionally_supported | 0 | null | null | unverifiable_no_results | not_assessed | efficacy |
CLAIM_RESULT_5a25493f9809 | CLUST_1fc4bc12851a1cbe | 28,076,671 | NCT01045655 | superiority_claim | worsened | statistically_supported | 0 | null | null | unverifiable_no_results | not_assessed | increased |
CLAIM_RESULT_6a69f8026a10 | CLUST_1fc4bc12851a1cbe | 28,076,671 | NCT01045655 | association_claim | worsened | directionally_supported | 0 | null | null | unverifiable_no_results | not_assessed | associated with |
CLAIM_RESULT_0ed797e47536 | CLUST_4ac918e56e5082e8 | 27,919,234 | NCT02796573 | superiority_claim | improved | directionally_supported | 0 | null | null | unverifiable_no_results | not_assessed | increased |
CLAIM_RESULT_cfdef296f25c | CLUST_4ac918e56e5082e8 | 27,919,234 | NCT02796573 | non_inferiority_claim | improved | directionally_supported | 0 | null | null | unverifiable_no_results | not_assessed | non-inferior |
CLAIM_RESULT_aa2e0fb5011c | CLUST_810799b0d0cb517e | 27,880,789 | NCT01905267 | superiority_claim | improved | statistically_supported | 2 | PRIMARY; SECONDARY | RESULT_c80be80fd799; RESULT_df83d0d43beb | checkable | not_assessed | reduced |
CLAIM_RESULT_dffe19e263e4 | CLUST_810799b0d0cb517e | 27,880,789 | NCT01905267 | association_claim | improved | directionally_supported | 2 | PRIMARY; SECONDARY | RESULT_c80be80fd799; RESULT_df83d0d43beb | checkable | not_assessed | associated with |
CLAIM_RESULT_e18e1848df81 | CLUST_9c76d8d2398ea3da | 27,871,643 | NCT02076425 | superiority_claim | improved | directionally_supported | 3 | OTHER_PRE_SPECIFIED; PRIMARY; SECONDARY | RESULT_510d7a0679bd; RESULT_ff3353871dcd; RESULT_f5a2fb0b293d | checkable | not_assessed | reduced |
MatrixNorm TrialEvidence — Depression
Structured, evidence-linked clinical-trial + biomedical-literature data extracted by MatrixNorm. Every record is provenance-stamped (source_url, raw_hash), carries its evidence trail (reasoning_atoms), and is honesty-gated — a claim is only statistically_supported when a p-value/CI/effect was present in the source, and normalized values keep their verbatim source_original_value.
Quality audit: PASS — 0 error(s), 0 warning(s), 5 note(s). See AUDIT_REPORT.md (ships with the dataset).
License
Creative Commons Attribution-NonCommercial 4.0 (cc-by-nc-4.0). Free to share and adapt for NON-COMMERCIAL use, with attribution. Commercial use requires a separate license from the publisher.
See LICENSE and SOURCES.md for attribution.
Files
All tables are relational — join on pmid, nct_id, evidence_group_id, result_id. Each ships as both .jsonl (full nested schema) and .csv (flattened, for the HF viewer / spreadsheets).
| File | Rows | What it is |
|---|---|---|
pubmed_packets.csv |
2,909 | One row per PubMed article (pmid). Titles, MeSH, journal, publication types, extracted evidence-claim signals. |
clinicaltrial_packets.csv |
863 | One row per trial (nct_id). Status, phase, conditions, interventions (with name_canonical), outcome/AE availability. |
trial_pubmed_links.csv |
2,562 | The NCT<->PMID bridge (join key for everything): link_type + strong/weak strength. |
evidence_groups.csv |
2,305 | One row per study cluster (evidence_group_id) — the paper(s)+trial(s) that belong together. |
trial_outcome_packets.csv |
2,643 | One row per reported outcome measure (result_id), with per-arm values and denominators. |
trial_adverse_event_packets.csv |
25,886 | One row per (adverse-event term x arm); frequency only when a denominator exists. |
claim_result_links.csv |
1,882 | Each PubMed claim linked to the trial result it can be checked against, with an honest checkability status. |
evidence_synthesis_efficacy_ranking.csv |
314 | Per-intervention count of statistically-supported efficacy claims (a backing count, NOT a ranking of effectiveness). |
What is NOT included
- The proprietary extraction engine (matrix routing / internal reasoning) is stripped from every record — only the generic data, ids, and evidence trail ship.
- No full article abstracts — only titles, MeSH, and short (<= ~25 char) evidence-span cue phrases.
- The held-out evaluation/test split is reserved for the licensed full dataset.
Caveat
The efficacy ranking is a COUNT of statistically-supported claims (study attention/replication), not a measure of real-world effectiveness or causation. Every synthesized asset carries this caveat and needs_human_review.
Source & full version
Produced by William TL Miller. See SOURCES.md for data provenance.
- Downloads last month
- 19